Saniona approved for listing on Nasdaq First North Premier and publishes company description

Saniona, a leading biotech company in the field of ion channels, today announces that Saniona has been approved for trading on Nasdaq First North Premier. Last day of trading on AktieTorget is Wednesday, 18 May 2016, and first day of trading on Nasdaq First North Premier is Thursday 19 May, 2016.

Saniona will continue to trade under the ticker SANION with the existing ISIN code SE0005794617. The Company's shareholders do not need to take any action in connection with the listing.

The Company has compiled a company description that has been approved by Nasdaq, which from today is available on the Company's website:

Pareto Securities AB will act as Certified Adviser for Saniona on Nasdaq First North Premier.

For more information, please contact

Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail:

About Saniona

Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Upsher-Smith Laboratories, Inc., Productos Medix, S.A de S.V and Saniona’s Boston based spinout Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at AktieTorget since April 2014 and has about 3,700 shareholders. The company’s share is traded under the ticker SANION. Read more at


Documents & Links